LU85511A1 - Nouvelles compositions injectables - Google Patents

Nouvelles compositions injectables Download PDF

Info

Publication number: LU85511A1
Authority: LU; Luxembourg
Prior art keywords: weight; particles; microns; metronidazole; suspension according
Prior art date: 1983-08-19

Application number

LU85511A

Other languages

English (en)

French (fr)

Inventor

Andrew Lewis

Robert Paul Haslam

John Howard Bell

Original Assignee

May & Baker Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-08-19

Filing date

1984-08-17

Publication date

1985-04-24

1984-08-17 Application filed by May & Baker Ltd filed Critical May & Baker Ltd

1985-04-24 Publication of LU85511A1 publication Critical patent/LU85511A1/fr

Links

239000007972 injectable composition Substances 0.000 title 1
239000002245 particle Substances 0.000 claims description 68
VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 62
229960000282 metronidazole Drugs 0.000 claims description 62
239000000725 suspension Substances 0.000 claims description 46
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical group OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 18
239000007900 aqueous suspension Substances 0.000 claims description 13
230000007935 neutral effect Effects 0.000 claims description 13
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 11
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 11
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 11
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 10
239000000375 suspending agent Substances 0.000 claims description 10
239000003755 preservative agent Substances 0.000 claims description 8
239000007864 aqueous solution Substances 0.000 claims description 7
239000003795 chemical substances by application Substances 0.000 claims description 7
235000019445 benzyl alcohol Nutrition 0.000 claims description 6
239000003630 growth substance Substances 0.000 claims description 6
241000499489 Castor canadensis Species 0.000 claims description 4
235000011779 Menyanthes trifoliata Nutrition 0.000 claims description 4
239000002253 acid Substances 0.000 claims description 4
150000007513 acids Chemical class 0.000 claims description 4
230000002335 preservative effect Effects 0.000 claims description 4
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 3
NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 3
238000007046 ethoxylation reaction Methods 0.000 claims description 3
239000000787 lecithin Substances 0.000 claims description 3
235000010445 lecithin Nutrition 0.000 claims description 3
229940067606 lecithin Drugs 0.000 claims description 3
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 2
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 2
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical class CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
-1 allyl sucrate Chemical compound 0.000 claims description 2
235000014113 dietary fatty acids Nutrition 0.000 claims description 2
239000000194 fatty acid Substances 0.000 claims description 2
229930195729 fatty acid Natural products 0.000 claims description 2
150000004665 fatty acids Chemical class 0.000 claims description 2
229920001059 synthetic polymer Polymers 0.000 claims description 2
239000000126 substance Substances 0.000 claims 3
239000012530 fluid Substances 0.000 claims 2
229940102213 injectable suspension Drugs 0.000 claims 2
238000002347 injection Methods 0.000 description 17
239000007924 injection Substances 0.000 description 17
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
239000000243 solution Substances 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
210000001124 body fluid Anatomy 0.000 description 8
239000010839 body fluid Substances 0.000 description 8
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
238000003756 stirring Methods 0.000 description 6
239000000203 mixture Substances 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
239000007787 solid Substances 0.000 description 4
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical class C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
239000010419 fine particle Substances 0.000 description 3
239000011521 glass Substances 0.000 description 3
239000008363 phosphate buffer Substances 0.000 description 3
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
238000000227 grinding Methods 0.000 description 2
239000001863 hydroxypropyl cellulose Substances 0.000 description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000000034 method Methods 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
239000012047 saturated solution Substances 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000000721 bacterilogical effect Effects 0.000 description 1
239000002585 base Substances 0.000 description 1
229960001631 carbomer Drugs 0.000 description 1
229960002242 chlorocresol Drugs 0.000 description 1
238000011109 contamination Methods 0.000 description 1
229930003836 cresol Natural products 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
239000000463 material Substances 0.000 description 1
230000035800 maturation Effects 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
239000008389 polyethoxylated castor oil Substances 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
241001148471 unidentified anaerobic bacterium Species 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Dermatology (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

LU85511A 1983-08-19 1984-08-17 Nouvelles compositions injectables LU85511A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB8322364		1983-08-19
GB838322364A GB8322364D0 (en)	1983-08-19	1983-08-19	Compositions of matter

Publications (1)

Publication Number	Publication Date
LU85511A1 true LU85511A1 (fr)	1985-04-24

Family

ID=10547557

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU85511A LU85511A1 (fr)	1983-08-19	1984-08-17	Nouvelles compositions injectables

Country Status (17)

Country	Link
JP (1)	JPS6067468A (it)
AU (1)	AU577055B2 (it)
BE (1)	BE900381A (it)
CA (1)	CA1214727A (it)
CH (1)	CH662812A5 (it)
DE (1)	DE3430354A1 (it)
DK (1)	DK165817C (it)
FR (1)	FR2560043B1 (it)
GB (2)	GB8322364D0 (it)
HU (1)	HU192990B (it)
IL (1)	IL72714A (it)
IT (1)	IT1213208B (it)
LU (1)	LU85511A1 (it)
NL (1)	NL8402510A (it)
NZ (1)	NZ209270A (it)
SE (1)	SE460095B (it)
ZA (1)	ZA846431B (it)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU205861B (en) *	1986-12-19	1992-07-28	Sandoz Ag	Process for producing hydrosole of pharmaceutically effective material
US7849856B2 (en)	2001-06-25	2010-12-14	3M Innovative Properties Company	Respirator valve

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB213928A (en) *	1923-04-06	1925-07-02	Deutsche Werke Ag	Improvements in or relating to compensated induction motors for single or polyphase alternating current
US3457348A (en) *	1966-06-27	1969-07-22	American Cyanamid Co	Stable syringeable suspensions of parenteral drugs in complex floc form
GB1430411A (en) *	1973-04-05	1976-03-31	May & Baker Ltd	Method and compositions for combating swine dysentery
US4029782A (en) *	1975-04-28	1977-06-14	Eli Lilly And Company	Cefazolin suspension for parenteral administration
GB2000025A (en) *	1977-05-14	1979-01-04	Pfizer Ltd	Nitroimidazole formulations
DE2932691A1 (de) *	1979-08-11	1981-04-09	Bayer Ag, 5090 Leverkusen	Antimykotische mittel mit hoeherer freisetzung der wirkstoffe

1983
- 1983-08-19 GB GB838322364A patent/GB8322364D0/en active Pending
1984
- 1984-08-13 IT IT8422323A patent/IT1213208B/it active
- 1984-08-15 NL NL8402510A patent/NL8402510A/nl not_active Application Discontinuation
- 1984-08-16 FR FR8412854A patent/FR2560043B1/fr not_active Expired
- 1984-08-17 DE DE19843430354 patent/DE3430354A1/de not_active Ceased
- 1984-08-17 LU LU85511A patent/LU85511A1/fr unknown
- 1984-08-17 HU HU843127A patent/HU192990B/hu not_active IP Right Cessation
- 1984-08-17 NZ NZ209270A patent/NZ209270A/en unknown
- 1984-08-17 AU AU32022/84A patent/AU577055B2/en not_active Ceased
- 1984-08-17 GB GB08420959A patent/GB2145088B/en not_active Expired
- 1984-08-17 JP JP59170517A patent/JPS6067468A/ja active Pending
- 1984-08-17 BE BE0/213510A patent/BE900381A/fr not_active IP Right Cessation
- 1984-08-17 CA CA000461262A patent/CA1214727A/en not_active Expired
- 1984-08-17 DK DK397084A patent/DK165817C/da not_active IP Right Cessation
- 1984-08-17 SE SE8404130A patent/SE460095B/sv not_active IP Right Cessation
- 1984-08-17 ZA ZA846431A patent/ZA846431B/xx unknown
- 1984-08-17 IL IL72714A patent/IL72714A/xx unknown
- 1984-08-17 CH CH3960/84A patent/CH662812A5/fr not_active IP Right Cessation

Also Published As

Publication number	Publication date
GB2145088A (en)	1985-03-20
CH662812A5 (fr)	1987-10-30
GB8420959D0 (en)	1984-09-19
ZA846431B (en)	1985-03-27
SE8404130D0 (sv)	1984-08-17
FR2560043A1 (fr)	1985-08-30
DE3430354A1 (de)	1985-03-07
IT8422323A0 (it)	1984-08-13
AU3202284A (en)	1985-02-21
SE8404130L (sv)	1985-02-20
DK165817C (da)	1993-06-21
DK165817B (da)	1993-01-25
CA1214727A (en)	1986-12-02
NZ209270A (en)	1988-02-29
HUT35650A (en)	1985-07-29
NL8402510A (nl)	1985-03-18
IL72714A (en)	1988-09-30
FR2560043B1 (fr)	1988-08-05
GB2145088B (en)	1986-10-08
GB8322364D0 (en)	1983-09-21
HU192990B (en)	1987-08-28
IT1213208B (it)	1989-12-14
SE460095B (sv)	1989-09-11
DK397084A (da)	1985-02-20
JPS6067468A (ja)	1985-04-17
BE900381A (fr)	1985-02-18
DK397084D0 (da)	1984-08-17
AU577055B2 (en)	1988-09-15

Publication	Publication Date	Title
FR2761265A1 (fr)	1998-10-02	Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs solvates
FR2853547A1 (fr)	2004-10-15	Compositions pharmaceutiques injectables contenant de la piperacilline et du tazobactame, et procede pour leur production
FR2588189A1 (fr)	1987-04-10	Composition pharmaceutique de type a transition de phase liquide-gel
US10842770B2 (en)	2020-11-24	Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
CA2052950A1 (en)	1992-04-11	Aqueous ophthalmic microemulsions of tepoxalin
KR102843054B1 (ko)	2025-08-05	멜록시캄 조성물, 제제 및 이의 제조 방법 및 응용
FR2458285A1 (fr)	1981-01-02	Preparation pharmaceutique transdermique au dinitrate d'isosorbide
CA3234595A1 (fr)	2023-05-16	Solution pharmaceutique d'hydrocortisone pour dispositif d'injection
FR2753376A1 (fr)	1998-03-20	Compositions pharmaceutiques comprenant de l'amisulpride et leurs applications therapeutiques
BE1000442A4 (fr)	1988-12-06	Composition therapeutique seche a base de sel de diclofenac.
LU85511A1 (fr)	1985-04-24	Nouvelles compositions injectables
FR2756736A1 (fr)	1998-06-12	Compositions pharmaceutiques contenant des derives de n-sulfonyl indoline
JP3917820B2 (ja)	2007-05-23	オザグレルナトリウム含有注射液およびその安定化方法
KR102066108B1 (ko)	2020-01-15	페닐링을 가지는 2종 화합물을 포함하는 화장료 조성물
BE1004051A4 (fr)	1992-09-15	Solution injectable et procede pour la preparer.
JP2013537554A (ja)	2013-10-03	改良された臓器移植の保存および許容のための組成物および方法
JP6598158B2 (ja)	2019-10-30	パロノセトロンを含有する安定な注射用液剤の製造方法
JP6189437B2 (ja)	2017-08-30	注射用抗生物質製剤およびその使用方法
EP0433140B1 (fr)	1993-03-31	Nouvelle préparation pharmaceutique anti-allergique à action prolongée
EP3328356A1 (de)	2018-06-06	Konzentrat enthaltend alprostadil
Agrawal et al.	2020	Studies on Release of Fluconazole from different Water Soluble PEG Ointment formulations
FR2793412A1 (fr)	2000-11-17	Formulations galeniques d'argatroban pour administration sous-cutanee
DE112023000659T5 (de)	2024-11-14	Neue Naproxen-Natrium-Präparate zur parenteralen Verabreichung
WO2024003503A1 (fr)	2024-01-04	Contenant en plastique comprenant une solution injectable de fentanyl
WO2025206172A1 (ja)	2025-10-02	電子線滅菌処理したヘテロシクリデンアセトアミド誘導体含有組成物